{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:27:45Z","timestamp":1722644865811},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11882-024-01155-9","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T08:01:58Z","timestamp":1718956918000},"page":"433-441","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing Symptoms of Systemic Sclerosis for the Allergist-Immunologist"],"prefix":"10.1007","volume":"24","author":[{"given":"Mehreen","family":"Elahee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn T.","family":"Domsic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"1155_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685\u201399.","journal-title":"Lancet"},{"key":"1155_CR2","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1093\/rheumatology\/keab190","volume":"60","author":"M Bairkdar","year":"2021","unstructured":"Bairkdar M, Rossides M, Westerlind H, Hesselstrand R, Arkema EV, Holmqvist M. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology. 2021;60:3121\u201333.","journal-title":"Rheumatology"},{"key":"1155_CR3","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.55563\/clinexprheumatol\/ki76s5","volume":"41","author":"M Di Battista","year":"2023","unstructured":"Di Battista M, Lepri G, Codullo V, Da Rio M, Fiorentini E, Della Rossa A, Guiducci S. Systemic sclerosis: one year in review 2023. Clin Exp Rheumatol. 2023;41:1567\u201374. https:\/\/doi.org\/10.55563\/clinexprheumatol\/ki76s5.","journal-title":"Clin Exp Rheumatol"},{"key":"1155_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2397198320915042","volume":"6","author":"ER Volkmann","year":"2021","unstructured":"Volkmann ER, Fischer A. Update on morbidity and mortality in systemic sclerosis\u2013related interstitial lung disease. J Scleroderma Relat Disord. 2021;6:11\u201320.","journal-title":"J Scleroderma Relat Disord"},{"key":"1155_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","volume":"51","author":"M Elhai","year":"2012","unstructured":"Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology. 2012;51:1017\u201326.","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"1155_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.20452\/pamw.1487","volume":"122","author":"S Bellando-Randone","year":"2012","unstructured":"Bellando-Randone S, Guiducci S, Matucci-Cerinic M. Very early diagnosis of systemic sclerosis. Pol Arch Med Wewn. 2012;122(Suppl 1):18\u201323.","journal-title":"Pol Arch Med Wewn"},{"key":"1155_CR7","first-page":"141","volume":"18","author":"S Guiducci","year":"2016","unstructured":"Guiducci S, Bellando-Randone S, Matucci-Cerinic M. A New Way of Thinking about Systemic Sclerosis: The Opportunity for a Very Early Diagnosis. Isr Med Assoc J. 2016;18:141\u20133.","journal-title":"Isr Med Assoc J"},{"key":"1155_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","volume":"12","author":"S Mehra","year":"2013","unstructured":"Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:340\u201354.","journal-title":"Autoimmun Rev"},{"key":"1155_CR9","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/art.38390","volume":"66","author":"SI Nihtyanova","year":"2014","unstructured":"Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, Wells AU, Denton CP. Prediction of Pulmonary Complications and Long-Term Survival in Systemic Sclerosis. Arthritis & Rheumatology. 2014;66:1625\u201335.","journal-title":"Arthritis & Rheumatology"},{"key":"1155_CR10","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747\u201355.","journal-title":"Ann Rheum Dis"},{"key":"1155_CR11","doi-asserted-by":"crossref","unstructured":"Cavazzana I, Vojinovic T, Airo\u2019 P, Fredi M, Ceribelli A, Pedretti E, Lazzaroni MG, Garrafa E, Franceschini F. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. Clin Rev Allergy Immunol. 2022;64:412\u2013430.","DOI":"10.1007\/s12016-022-08946-w"},{"key":"1155_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","volume":"37","author":"Y Hamaguchi","year":"2010","unstructured":"Hamaguchi Y,. Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis. J Dermatol. 2010;37:42\u201353.","journal-title":"J Dermatol"},{"key":"1155_CR13","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/art.42152","volume":"74","author":"S Suresh","year":"2022","unstructured":"Suresh S, Charlton D, Snell EK, Laffoon M, Medsger TA, Zhu L, Domsic RT. Development of Pulmonary Hypertension in Over One-Third of Patients With Th\/To Antibody-Positive Scleroderma in Long-Term Follow-Up. Arthritis & Rheumatology. 2022;74:1580\u20137.","journal-title":"Arthritis & Rheumatology"},{"key":"1155_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1046\/j.1365-2249.1999.00961.x","volume":"117","author":"H Ihn","year":"2001","unstructured":"Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Sato S, Kikuchi K, Tamaki K. Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol. 2001;117:383\u20137.","journal-title":"Clin Exp Immunol"},{"key":"1155_CR15","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1136\/annrheumdis-2013-203716","volume":"73","author":"T Minier","year":"2014","unstructured":"Minier T, Guiducci S, Bellando-Randone S, et al. Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis. 2014;73:2087\u201393.","journal-title":"Ann Rheum Dis"},{"key":"1155_CR16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/ard.2010.136929","volume":"70","author":"J Avouac","year":"2011","unstructured":"Avouac J, Fransen J, Walker U, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70:476\u201381.","journal-title":"Ann Rheum Dis"},{"key":"1155_CR17","first-page":"123","volume":"113","author":"KK Temprano","year":"2016","unstructured":"Temprano KK. A Review of Raynaud\u2019s Disease. Mo Med. 2016;113:123\u20136.","journal-title":"Mo Med"},{"key":"1155_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/bcp.12912","volume":"82","author":"C Khouri","year":"2016","unstructured":"Khouri C, Blaise S, Carpentier P, Villier C, Cracowski J-L, Roustit M. Drug-induced Raynaud\u2019s phenomenon: beyond \u03b2-adrenoceptor blockers. Br J Clin Pharmacol. 2016;82:6\u201316.","journal-title":"Br J Clin Pharmacol"},{"key":"1155_CR19","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00296-018-4119-9","volume":"38","author":"O Qiu","year":"2018","unstructured":"Qiu O, Chan T, Luen M, Cruz JE, Hermes-DeSantis ER. Use of nitroglycerin ointment to treat primary and secondary Raynaud\u2019s phenomenon: a systematic literature review. Rheumatol Int. 2018;38:2209\u201316.","journal-title":"Rheumatol Int"},{"key":"1155_CR20","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","volume":"40","author":"B Coleiro","year":"2001","unstructured":"Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM. Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology. 2001;40:1038\u201343.","journal-title":"Rheumatology"},{"key":"1155_CR21","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaad.2018.01.043","volume":"78","author":"P Curtiss","year":"2018","unstructured":"Curtiss P, Schwager Z, Cobos G, Lo Sicco K, Franks AG. A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud\u2019s phenomenon. J Am Acad Dermatol. 2018;78:1110-1118.e3.","journal-title":"J Am Acad Dermatol"},{"key":"1155_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70:32\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1155_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/2397198318823951","volume":"4","author":"A Fern\u00e1ndez-Codina","year":"2019","unstructured":"Fern\u00e1ndez-Codina A, Ca\u00f1as-Ruano E, Pope JE. Management of Raynaud\u2019s phenomenon in systemic sclerosis\u2014a practical approach. J Scleroderma Relat Disord. 2019;4:102\u201310.","journal-title":"J Scleroderma Relat Disord"},{"key":"1155_CR24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12016-017-8625-4","volume":"53","author":"C Ferreli","year":"2017","unstructured":"Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol. 2017;53:306\u201336.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1155_CR25","doi-asserted-by":"publisher","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","volume":"11","author":"VK Jaeger","year":"2016","unstructured":"Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS ONE. 2016;11:e0163894.","journal-title":"PLoS ONE"},{"key":"1155_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5301\/jsrd.5000231","volume":"2","author":"D Khanna","year":"2017","unstructured":"Khanna D, Furst DE, Clements PJ, et al. Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. J Scleroderma Relat Disord. 2017;2:11\u20138.","journal-title":"J Scleroderma Relat Disord"},{"key":"1155_CR27","first-page":"166","volume":"31","author":"TM Frech","year":"2013","unstructured":"Frech TM, Shanmugam VK, Shah AA, et al. Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol. 2013;31:166\u201371.","journal-title":"Clin Exp Rheumatol"},{"key":"1155_CR28","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","volume":"3","author":"S Ebata","year":"2021","unstructured":"Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3:e489\u201397.","journal-title":"Lancet Rheumatol"},{"key":"1155_CR29","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","volume":"41","author":"VD Steen","year":"1998","unstructured":"Steen VD, Medsger TA. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41:1613\u20139.","journal-title":"Arthritis Rheum"},{"key":"1155_CR30","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/acr.20257","volume":"62","author":"G El-Baalbaki","year":"2010","unstructured":"El-Baalbaki G, Razykov I, Hudson M, Bassel M, Baron M, Thombs BD. Association of pruritus with quality of life and disability in systemic sclerosis. Arthritis Care Res (Hoboken). 2010;62:1489\u201395.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1155_CR31","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/j.1468-3083.2006.01647.x","volume":"20","author":"H Van Os-Medendorp","year":"2006","unstructured":"Van Os-Medendorp H, Eland-de Kok P, Grypdonck M, Bruijnzeel-Koomen C, Ros W. Prevalence and predictors of psychosocial morbidity in patients with chronic pruritic skin diseases. J Eur Acad Dermatol Venereol. 2006;20:810\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1155_CR32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2340\/00015555-2980","volume":"98","author":"G Gourier","year":"2018","unstructured":"Gourier G, Th\u00e9r\u00e9n\u00e9 C, Mazeas M, et al. Clinical Characteristics of Pruritus in Systemic Sclerosis Vary According to the Autoimmune Subtype. Acta Derm Venereol. 2018;98:735\u201341.","journal-title":"Acta Derm Venereol"},{"key":"1155_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/804296","volume":"2011","author":"T Frech","year":"2011","unstructured":"Frech T, Novak K, Revelo MP, Murtaugh M, Markewitz B, Hatton N, Scholand MB, Frech E, Markewitz D, Sawitzke AD. Low-Dose Naltrexone for Pruritus in Systemic Sclerosis. Int J Rheumatol. 2011;2011:1\u20135.","journal-title":"Int J Rheumatol"},{"key":"1155_CR34","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nrneurol.2014.99","volume":"10","author":"L Misery","year":"2014","unstructured":"Misery L, Brenaut E, Le Garrec R, Abasq C, Genestet S, Marcorelles P, Zagnoli F. Neuropathic pruritus. Nat Rev Neurol. 2014;10:408\u201316.","journal-title":"Nat Rev Neurol"},{"key":"1155_CR35","doi-asserted-by":"publisher","first-page":"adv00869","DOI":"10.2340\/actadv.v103.5346","volume":"103","author":"Y Han","year":"2023","unstructured":"Han Y, Woo YR, Cho SH, Lee JD, Kim HS. Itch and Janus Kinase Inhibitors. Acta Derm Venereol. 2023;103:adv00869.","journal-title":"Acta Derm Venereol"},{"key":"1155_CR36","doi-asserted-by":"publisher","first-page":"1759720X2110324","DOI":"10.1177\/1759720X211032437","volume":"13","author":"KE Konopka","year":"2021","unstructured":"Konopka KE, Myers JL. Interstitial lung disease pathology in systemic sclerosis. Ther Adv Musculoskelet Dis. 2021;13:1759720X2110324.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1155_CR37","doi-asserted-by":"publisher","first-page":"1902026","DOI":"10.1183\/13993003.02026-2019","volume":"55","author":"O Distler","year":"2020","unstructured":"Distler O, Assassi S, Cottin V, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J. 2020;55:1902026.","journal-title":"Eur Respir J"},{"key":"1155_CR38","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019;380:2518\u201328.","journal-title":"N Engl J Med"},{"key":"1155_CR39","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/art.41668","volume":"73","author":"D Roofeh","year":"2021","unstructured":"Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP, Huang S, Khanna D. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis & Rheumatology. 2021;73:1301\u201310.","journal-title":"Arthritis & Rheumatology"},{"key":"1155_CR40","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","volume":"19","author":"JE Pope","year":"2023","unstructured":"Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T. State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol. 2023;19:212\u201326.","journal-title":"Nat Rev Rheumatol"},{"key":"1155_CR41","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8:963\u201374.","journal-title":"Lancet Respir Med"},{"key":"1155_CR42","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387:2630\u201340.","journal-title":"Lancet"},{"key":"1155_CR43","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1007\/s10067-020-05542-1","volume":"40","author":"S Borrirukwisitsak","year":"2021","unstructured":"Borrirukwisitsak S, Tantayakom P, Katchamart W. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis. Clin Rheumatol. 2021;40:2779\u201389.","journal-title":"Clin Rheumatol"},{"key":"1155_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11:45\u201354.","journal-title":"Lancet Respir Med"},{"key":"1155_CR45","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","volume":"40","author":"N Acharya","year":"2020","unstructured":"Acharya N, Sharma SK, Mishra D, Dhooria S, Dhir V, Jain S. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease\u2014a randomised controlled trial. Rheumatol Int. 2020;40:703\u201310.","journal-title":"Rheumatol Int"},{"key":"1155_CR46","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708\u201319.","journal-title":"Lancet Respir Med"},{"key":"1155_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41584-023-01044-x","volume":"20","author":"V Liakouli","year":"2024","unstructured":"Liakouli V, Ciancio A, Del Galdo F, Giacomelli R, Ciccia F. Systemic sclerosis interstitial lung disease: unmet needs and potential solutions. Nat Rev Rheumatol. 2024;20:21\u201332.","journal-title":"Nat Rev Rheumatol"},{"key":"1155_CR48","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13075-017-1250-z","volume":"19","author":"K Morrisroe","year":"2017","unstructured":"Morrisroe K, Stevens W, Sahhar J, Rabusa C, Nikpour M, Proudman S. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. Arthritis Res Ther. 2017;19:42.","journal-title":"Arthritis Res Ther"},{"key":"1155_CR49","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1002\/art.21433","volume":"52","author":"E Hachulla","year":"2005","unstructured":"Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheum. 2005;52:3792\u2013800.","journal-title":"Arthritis Rheum"},{"key":"1155_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/2045-8932.109919","volume":"3","author":"G Strange","year":"2013","unstructured":"Strange G, Gabbay E, Kermeen F, Williams T, Carrington M, Stewart S, Keogh A. Time from Symptoms to Definitive Diagnosis of Idiopathic Pulmonary Arterial Hypertension: The Delay Study. Pulm Circ. 2013;3:89\u201394.","journal-title":"Pulm Circ"},{"key":"1155_CR51","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1378\/chest.13-3014","volume":"146","author":"L Chung","year":"2014","unstructured":"Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM, McGoon M, Nicolls MR, Zamanian RT. Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry. Chest. 2014;146:1494\u2013504.","journal-title":"Chest"},{"key":"1155_CR52","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","volume":"371","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. The Lancet. 2008;371:2093\u2013100.","journal-title":"The Lancet"},{"key":"1155_CR53","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/art.10775","volume":"48","author":"V Steen","year":"2003","unstructured":"Steen V, Medsger TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48:516\u201322.","journal-title":"Arthritis Rheum"},{"key":"1155_CR54","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0023-2019","volume":"28","author":"J Weatherald","year":"2019","unstructured":"Weatherald J, Montani D, Jevnikar M, Ja\u00efs X, Savale L, Humbert M. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev. 2019;28: 190023.","journal-title":"Eur Respir Rev"},{"key":"1155_CR55","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","volume":"73","author":"JG Coghlan","year":"2014","unstructured":"Coghlan JG, Denton CP, Gr\u00fcnig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73:1340\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1155_CR56","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","volume":"53","author":"G Simonneau","year":"2019","unstructured":"Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913.","journal-title":"Eur Respir J"},{"key":"1155_CR57","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/OARRR.S228234","volume":"11","author":"D Saygin","year":"2019","unstructured":"Saygin D, Domsic RT. <p>Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment<\/p>. Open Access Rheumatol. 2019;11:323\u201333.","journal-title":"Open Access Rheumatol"},{"key":"1155_CR58","doi-asserted-by":"publisher","first-page":"e31780","DOI":"10.1097\/MD.0000000000031780","volume":"101","author":"M Nassar","year":"2022","unstructured":"Nassar M, Ghernautan V, Nso N, et al. Gastrointestinal involvement in systemic sclerosis: An updated review. Medicine. 2022;101:e31780.","journal-title":"Medicine"},{"key":"1155_CR59","first-page":"763","volume":"92","author":"G Lock","year":"1997","unstructured":"Lock G, Holstege A, Lang B, Sch\u00f6lmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol. 1997;92:763\u201371.","journal-title":"Am J Gastroenterol"},{"key":"1155_CR60","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41598-020-57636-0","volume":"10","author":"C Foocharoen","year":"2020","unstructured":"Foocharoen C, Chunlertrith K, Mairiang P, Mahakkanukrauh A, Suwannaroj S, Namvijit S, Wantha O, Nanagara R. Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study. Sci Rep. 2020;10:769.","journal-title":"Sci Rep"},{"key":"1155_CR61","doi-asserted-by":"publisher","first-page":"e795","DOI":"10.1016\/S2665-9913(22)00183-7","volume":"4","author":"M Hughes","year":"2022","unstructured":"Hughes M, Allanore Y, Baron M, et al. Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease. Lancet Rheumatol. 2022;4:e795\u2013803.","journal-title":"Lancet Rheumatol"},{"key":"1155_CR62","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/1529-0131(200108)45:4<346::AID-ART347>3.0.CO;2-L","volume":"45","author":"I Marie","year":"2001","unstructured":"Marie I, Dominique S, Levesque H, Ducrott\u00e9 P, Denis P, Hellot MF, Courtois H. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum. 2001;45:346\u201354.","journal-title":"Arthritis Rheum"},{"key":"1155_CR63","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4253\/wjge.v5.i1.6","volume":"5","author":"L Fuccio","year":"2013","unstructured":"Fuccio L. Diagnosis and management of gastric antral vascular ectasia. World J Gastrointest Endosc. 2013;5:6.","journal-title":"World J Gastrointest Endosc"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-024-01155-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T12:51:57Z","timestamp":1722603117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-024-01155-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1155"],"URL":"https:\/\/doi.org\/10.1007\/s11882-024-01155-9","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"type":"print","value":"1529-7322"},{"type":"electronic","value":"1534-6315"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"3 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Mehreen Elahee and Robyn T Dos has no conflict of interest. Robyn T Domsic has received consulting funds from Astra-Zeneca and Aisa Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}